Background. Gastrointestinal (GI) cancers are one of the most relevant causes of death globally, frequently associated with poor dietary patterns. The Mediterranean Diet (MedDiet) contributes to cancer prevention. To assess adherence to MedDiet, our research group validated a new score, the Chrono Med Diet Score (CMDS), that captures increased visceral adiposity. Methods. We enrolled 401 subjects who underwent an evaluation for metabolic diseases, specific screening procedures according to current guidelines, and were asked to answer to CMDS. A total of 71 new cancer cases were recorded, including 40 GI and 31 non-gastrointestinal (NON-GI) cancers. Re-sults. We found that CMDS was reduced in subjects who were diagnosed with cancers. Patients who reported a CMDS score of 12 or less had an over three times increased risk to be diagnosed GI cancers and presented increased waist circumference and triglycerides and reduced HDL-cholesterol, if compared to adherent subjects. Conclusion. Low CMDS values capture the risk for cancer diagnosis, especially for GI cancers. Thus, CMDS, along with Waist Circumference, can be considered as a bona fide marker for increased risk of cancer, requiring anticipated screening procedures for detection of premalignant and early-stage GI cancers in patients with low adher-ence to MedDiet.
Low Adherence to Mediterranean Diet Characterizes Metabolic Patients with Gastrointestinal Cancer
Carlo De Matteis;Lucilla Crudele;Raffaella Maria Gadaleta;Ersilia Di Buduo;Fabio Novielli;Stefano Petruzzelli;Cariello M;Antonio Moschetta
2024-01-01
Abstract
Background. Gastrointestinal (GI) cancers are one of the most relevant causes of death globally, frequently associated with poor dietary patterns. The Mediterranean Diet (MedDiet) contributes to cancer prevention. To assess adherence to MedDiet, our research group validated a new score, the Chrono Med Diet Score (CMDS), that captures increased visceral adiposity. Methods. We enrolled 401 subjects who underwent an evaluation for metabolic diseases, specific screening procedures according to current guidelines, and were asked to answer to CMDS. A total of 71 new cancer cases were recorded, including 40 GI and 31 non-gastrointestinal (NON-GI) cancers. Re-sults. We found that CMDS was reduced in subjects who were diagnosed with cancers. Patients who reported a CMDS score of 12 or less had an over three times increased risk to be diagnosed GI cancers and presented increased waist circumference and triglycerides and reduced HDL-cholesterol, if compared to adherent subjects. Conclusion. Low CMDS values capture the risk for cancer diagnosis, especially for GI cancers. Thus, CMDS, along with Waist Circumference, can be considered as a bona fide marker for increased risk of cancer, requiring anticipated screening procedures for detection of premalignant and early-stage GI cancers in patients with low adher-ence to MedDiet.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
